Corrigendum: Case Report: Durable response to immuno-chemotherapy in a case of ROS1 fusion-positive advanced lung adenocarcinoma: A case report.

Yan, Ningning; Huang, Siyuan; Li, Linlin; Guo, Qianqian; Geng, Di; Zhang, Huixian; Guo, Sanxing; Li, Xingya.

Afiliação

Yan N; Department of Medical Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Huang S; Department of Medical Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Li L; Department of Medical Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Guo Q; Department of Medical Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Geng D; Department of Medical Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Zhang H; Department of Medical Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Guo S; Department of Medical Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Li X; Department of Medical Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

Front Pharmacol ; 14: 1256801, 2023.

Article em En | MEDLINE | ID: mdl-37576810